Evaluating Nerandomilast in Pulmonary Fibrosis: Learning Lessons From the Clinical Development Program
- How did the preclinical and translational data inform the design of the phase II and phase III trials? What were the key trial design features, patient populations, endpoints, and readouts that contributed to the successful outcome?
- How were the insights from both preclinical and clinical stages integrated into a cohesive development strategy that led to a positive phase III readout? What can we learn for future trials in IPF?